Scarica l'app Stockscreener
2.36
14.01%
0.29
Dopo l'orario di chiusura:
2.32
-0.04
-1.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
Immunitybio Inc earnings missed by $0.02, revenue fell short of estimates - Investing.com
ImmunityBio Q1 Loss Narrows, Revenue Rises - marketscreener.com
ImmunityBio: Q1 Earnings Snapshot - San Antonio Express-News
ImmunityBio, Inc. SEC 10-Q Report - TradingView
Earnings Flash (IBRX) IMMUNITYBIO INC. Reports Q1 Revenue $16.5M, vs. FactSet Est of $16.0M - marketscreener.com
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Is ImmunityBio, Inc. (IBRX) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
‘Arbitrary’ FDA decision-making puts U.S. innovation at risk, says Soon-Shiong - biocentury.com
ImmunityBio (IBRX) Faces FDA Setback in Bladder Cancer Therapy A - GuruFocus
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive By Stocktwits - Investing.com India
ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive - MSN
ImmunityBio (IBRX) Faces Filing Setback with FDA's Unanticipated Response | IBRX Stock News - GuruFocus
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
Unity lays off ‘all’ workers; Novo to get FDA decision on oral Wegovy this year - Endpoints News
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug - Benzinga
ImmunityBio stock sinks after FDA issues RTF letter By Investing.com - Investing.com Nigeria
ImmunityBio stock sinks after FDA issues RTF letter - Investing.com Australia
ImmunityBio (IBRX) Faces Setback with FDA Refusal for Cancer Tre - GuruFocus
ImmunityBio Seeks Urgent FDA Meeting After Rejection for Bladder Cancer Therapy - marketscreener.com
ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency'S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May - marketscreener.com
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 20 - Business Wire
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting - The Globe and Mail
Wainwright maintains $8 target on ImmunityBio shares post-AUA By Investing.com - Investing.com India
Wainwright maintains $8 target on ImmunityBio shares post-AUA - Investing.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of ImmunityBio, Inc.(IBRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
IBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio's Bladder Cancer Treatment Shows High Cystectomy Avoidance, Long-Term Response - marketscreener.com
IBRX Study Reveals Promising Results for Non-Muscle Invasive Bla - GuruFocus
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up - marketscreener.com
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best i - StreetInsider
SHAREHOLDER ALERT: Potential Recovery for ImmunityBio, Inc. (IBRX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC - OncLive
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - BioSpace
Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Insider Monkey
Economic Uncertainties Batter Trading in These 10 Firms - Insider Monkey
ImmunityBio sees Q1 sales surge, submits FDA applications By Investing.com - Investing.com South Africa
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - BioSpace
ImmunityBio Completes FDA License Application Submissions - marketscreener.com
Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia - marketscreener.com
ImmunityBio sees Q1 sales surge, submits FDA applications - Investing.com
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):